Recurrent Squamous Cell Carcinoma of the Hypopharynx Completed Phase 2 Trials for Paclitaxel (DB01229)

IndicationStatusPhase
DBCOND0029504 (Recurrent Squamous Cell Carcinoma of the Hypopharynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01316757Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerTreatment